Zobrazeno 1 - 10
of 4 980
pro vyhledávání: '"Anti-CD20"'
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 5011-5015 (2024)
Masafumi Seki, Chie Kubosawa, Makoto Ono, Fumitaka Kamoshita, Atsuko Shimizu, Kotaro Mitsutake Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, JapanCorrespondence: Masafumi
Externí odkaz:
https://doaj.org/article/9c577554de274623a6ebe79d098ed4b9
Autor:
Jinqiu Su, Zhuang Li, Jianli Wang, Nairong Liu, Liyi Bao, Jiayuan Du, Yan Li, Yaojie Yu, He Wang
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-8 (2024)
Abstract Purpose To determine the effects of anti-B cell surface marker CD20 antibody on the occurrence and progression of endometrial cancer to provide insights into clinical treatment in the future. Methods We performed a two-sample Mendelian rando
Externí odkaz:
https://doaj.org/article/1126bdb5abfe463c8e15d668b8c2478b
Autor:
Shuhei Maruyama, Daiki Wada, Shuji Kanayama, Haruka Shimazu, Yumiko Miyano, Akira Inoue, Masami Kashihara, Kazuyuki Okuda, Fukuki Saito, Yasushi Nakamori, Kazuyoshi Ishii, Yasuyuki Kuwagata
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The global impact of the coronavirus disease 2019 (COVID-19) pandemic has resulted in significant morbidity and mortality. Immunocompromised patients, particularly those treated for B-cell lymphoma, have shown an increased risk of
Externí odkaz:
https://doaj.org/article/b592cfcb34954d57bfe0b10c958809e9
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 3025-3042 (2024)
Sarah-Jane Martin,1,2 Melanie Guenette,1 Jiwon Oh1 1Division of Neurology, Department of Medicine, St Michael’s Hospital, Toronto, Canada; 2University of Glasgow, Glasgow, UKCorrespondence: Jiwon Oh, Email jiwon.oh@unityhealth.toAbstract: B cells a
Externí odkaz:
https://doaj.org/article/b4c07be9cd14429ba1894b22c11ed442
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Antibody-dependent cellular phagocytosis (ADCP) by monocytes and macrophages contributes significantly to the efficacy of many therapeutic monoclonal antibodies (mAbs), including anti-CD20 rituximab (RTX) targeting CD20+ B-cell non-Hodgkin lymphomas
Externí odkaz:
https://doaj.org/article/89cbae7d553a4901a0c53c5d3f712f6b
Autor:
Enrique Alvarez, Lawrence Steinman, Edward J. Fox, Hans-Peter Hartung, Peiqing Qian, Sibyl Wray, Derrick Robertson, Krzysztof Selmaj, Daniel Wynn, Koby Mok, Yihuan Xu, Karthik Bodhinathan, Hari P. Miskin, Bruce A. C. Cree
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
BackgroundUblituximab is a novel anti-CD20 monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicity. The phase 3 ULTIMATE I and II studies showed significant improvements in annualized relapse rate, total number of ga
Externí odkaz:
https://doaj.org/article/130d74d067b24a7298186ec6d38aa0d2
Autor:
Hélène Bartak, Tasnim Fareh, Nouha Ben Othman, Delphine Viard, Mikael Cohen, Fanny Rocher, Elliot Ewig, Milou-Daniel Drici, Christine Lebrun-Frenay
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 917-930 (2024)
Abstract Introduction Over the past few years, anti-CD20 therapies like rituximab, ocrelizumab or ofatumumab have seen an increase in interest in the treatment of neurological autoimmune disorders such as multiple sclerosis (MS), neuromyelitis optica
Externí odkaz:
https://doaj.org/article/68c221405b3a4e8c8d9ce0e267db9995
Autor:
Frederik Novak, Anna Christine Nilsson, Emil Birch Christensen, Caroline Louise Stougaard, Mike Bogetofte Barnkob, Dorte K. Holm, Agnes Hauschultz Witt, Keld-Erik Byg, Isik S. Johansen, Christian Nielsen, Tobias Sejbaek
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThis study examines the humoral and cellular response in multiple sclerosis (MS) patients on anti-CD20 therapy before and after the 1st to 4th BNT162b2 mRNA SARS-CoV-2 vaccination and the relationship with breakthrough infection.MethodsPart
Externí odkaz:
https://doaj.org/article/4bf15d137f534304ac83518451328cd4
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 3, Pp 101286- (2024)
Although the last decade has seen tremendous progress in drugs that treat cystic fibrosis (CF) due to mutations that lead to protein misfolding, there are approximately 8%–10% of subjects with mutations that result in no significant CFTR protein ex
Externí odkaz:
https://doaj.org/article/472d5f630d7b4844bbaea67e9bc44cca
Autor:
Yuankai Shi, Keshu Zhou, Hui Zhou, Yan Qin, Hongmei Jing, Ying Xiang, Zhao Wang, Zhen Wang, Aimin Zang, Ou Bai, Zhenyu Li, Huilai Zhang, Yongping Song, Jinjin Liang, Min Wei
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102702- (2024)
Summary: Background: MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, with a nearly completely afucosylated N-glycans in Fc region, has demonstrated superior activity compared with rituximab and obinutuzumab in vitro and in vivo
Externí odkaz:
https://doaj.org/article/2a3c6df3d77e4c00af3f193cded6e60d